I thank the Member for the question. Prostate cancer is a particular area of focus, and not just because there is a very active—and I welcome their activity—third sector organisation around prostate cancer, who regularly encourage us to find out more for ourselves and to encourage others to think about the current ways of understanding whether people do have prostate cancer and the potential treatment options. Part of the challenge is that we currently have a less than adequate test for prostate cancer, and it’s part of the uncertainty that goes into that. We are interested in advancing the evidence base for more effective tests to understand whether people have prostate cancer and what particular type of prostate cancer, and the evidence you cite from ‘The Lancet’ is just one of those. We need to understand all of that evidence, and understand how much of that goes into diagnosis and how much goes into screening as well. This is one of those areas where demand and a desire to have a wider screening test—we need to know whether there’s evidence that the screening test is actually the right thing to do, as opposed to different forms of diagnosis where there is a suspicion of prostate cancer. As ever, in this area and others, we will continue to be guided by the very best evidence and the very best return in terms of patient outcomes from any new form of screening or diagnosis.